oleoyl chloride | 7378-94-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: oleoyl chloride
• 英文别名: 9-Octadecenoyl chloride, (9Z)-；octadec-9-enoyl chloride
• CAS: 7378-94-1
• 化学式: C₁₈H₃₃ClO
• 分子量: 300.912
• InChiKey: MLQBTMWHIOYKKC-UHFFFAOYSA-N

物化性质

• 物理描述：
  Liquid

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  20
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  oleoyl chloride 在 2-[(CH₃)2NCH₂](C₆H₄)(n-Bu)2SnF 作用下， 以 乙醚 为溶剂， 反应 0.17h， 以100%的产率得到oleoyl fluoride
  参考文献：
  名称：

  C，N螯合的二正丁基锡（IV）氟化物在酰基氟，氟甲酸酯和氟光气的合成中的用途

  摘要：

  {2-[（CH 3）2 NCH 2 ] C 6 H 4 }（n- Bu）2 SnF（1）与各种氯甲酸酯，酰氯，甲磺酰氯，4,4'-二甲氧基三苯甲基氯和光气前体或衍生物反应形成氟化类似物。所有反应均在温和条件下快速进行。在甲苯中使用催化量的1和KF导致选择的氟甲酸酯的产率较高。

  DOI：

  10.1016/j.tetlet.2008.08.060
• 作为产物：
  描述：

  油酸 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 oleoyl chloride
  参考文献：
  名称：

  Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids

  摘要：

  This work describes the synthesis of a series of fatty acid hydrazide derivatives of isoniazid (INH). The compounds were tested against Mycobacterium tuberculosis H37Rv (ATCC 27294) as well as INH-resistant (ATCC 35822 and 1896 HF) and rifampicin-resistant (ATCC 35338) M. tuberculosis strains. The fatty acid derivatives of INH showed high antimycobacterial potency against the studied strains, which is desirable for a pharmaceutical compound, suggesting that the increased lipophilicity of isoniazid plays an important role in its antimycobacterial activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.09.034

文献信息

• UNSATURATED FATTY ACID MONOESTERS AND DIESTERS ON ASCORBIC ACID AND COSMETIC USES THEREOF
  申请人：Poigny Stéphane

  公开号：US20120076744A1

  公开（公告）日：2012-03-29

  The present invention relates to a compound with the following general formula (I): in which: R 1 is a hydrocarbon chain of an unsaturated fatty acid from C 12 to C 24 including at least one unsaturation; and R 2 and R 3 are, independently or simultaneously: a hydrogen or a C 1 -C 3 alkyl or a phenyl; and R 4 : a hydrogen atom or COR 1′ , where R 1′ is a hydrocarbon chain of an unsaturated fatty acid from C 12 to C 24 including at least one unsaturation, advantageously 1 to 6 and preferably 1 to 4.

  本发明涉及具有以下一般式（I）的化合物： 其中：R1是来自C12到C24的不饱和脂肪酸的烃链，包括至少一个不饱和度；而R2和R3是独立或同时的：氢或C1-C3烷基或苯基；而R4：氢原子或COR1'，其中R1'是来自C12到C24的不饱和脂肪酸的烃链，有利地为1到6，优选为1到4。
• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] TREATMENT OF NEURODEGENERATIVE CONDITIONS<br/>[FR] TRAITEMENT D'ETATS NEURODEGENERATIFS
  申请人：BTG INT LTD

  公开号：WO2005018632A1

  公开（公告）日：2005-03-03

  A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of Ϝ-linolenic acid, dihomo-Ϝ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.

  提供了一种治疗神经退行性疾病患者的方法，包括向该患者施用含有甘油基团和脂肪酸基团的治疗有效剂量的脂质甘油酯，所述脂肪酸基团选自Ϝ-亚麻酸、二油酸和花生四烯酸组成的群体，其特点在于所选的脂肪酸基团附着在甘油基团的sn-2位置。最好的方法是，脂质被施用的持续时间和剂量足以维持或提高患者体内TGF-β1水平至治疗水平。
• CRYSTAL OF CYCLIC PHOSPHONIC ACID SODIUM SALT AND METHOD FOR MANUFACTURING SAME
  申请人：OTSUKA CHEMICAL CO., LTD.

  公开号：US20170233421A1

  公开（公告）日：2017-08-17

  An object of the present invention is to provide a crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal. The present invention provides a crystal of a cyclic phosphonic acid sodium salt (2ccPA) represented by formula (1):

  本发明的目的是提供一种具有高纯度和优异储存稳定性的环磷酸钠盐晶体（2ccPA）以及制备该晶体的方法。本发明提供了一种由化学式（1）表示的环磷酸钠盐（2ccPA）的晶体：
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。